Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $130.
August 05, 2024 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Axsome Therapeutics and maintained a price target of $130.
The reiteration of a Buy rating and the maintenance of a $130 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100